Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention

Trends in Molecular Medicine

Volumn 8, Issue 2, 2002, Pages 82-88

  Park, Woo Chan ^a   Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; ACOLBIFENE; ARZOXIFENE; ESTROGEN RECEPTOR; IDOXIFENE; LASOFOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

BONE DENSITY; BREAST CANCER; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG MECHANISM; FEMALE; HUMAN; OSTEOPOROSIS; REVIEW;

EID: 0036154287     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(02)02282-7     Document Type: Review

References (57)

1. Steroid hormone receptors in breast cancer management
2. On the treatment of inoperable cases of the carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases
3. Hormonal pathogenesis of adenocarcinoma of the breast
4. Oestrogen-responsive human breast cancer in long-term tissue culture
5. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata
6. Species-specific pharmacology of antiestrogens: Role of metabolism
7. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse
8. Effects of anti-estrogens on bone in castrated and intact female rats
9. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model
10. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
11. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study
12. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
13. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial
14. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen
15. Contrasting effects of conjugated estrogens and tamoxifen on dilator responses of atherosclerotic epicardial coronary arteries in nonhuman primates
16. Cardiovascular effects of tamoxifen in women with and without heart disease: Breast cancer prevention trial
17. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
18. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial
19. Gynecologic effects of tamoxifen and the association with endometrial carcinoma
20. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
21. Tamoxifen for early breast cancer: An overview of the randomised trials
22. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
23. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study
24. A brief review of the current breast cancer prevention trials and proposals for future trials
25. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study
26. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
27. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer
28. Raloxifene hydrochloride
29. Phase II evaluation of Ly156758 in metastatic breast cancer
30. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
31. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
32. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial. Multiple outcomes of raloxifene evaluation
33. Development of antiestrogens and their use in breast cancer: Eighth Cain memorial award lecture
34. Tamoxifen, raloxifene, and the prevention of breast cancer
35. Raloxifene as a multifunctional medicine? Current trials will show whether it is effective in both osteoporosis and breast cancer
36. Cloning of a novel receptor expressed in rat prostate and ovary
37. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β
38. Molecular basis of agonism and antagonism in the oestrogen receptor
39. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain
40. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor
41. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351
42. Molecular mechanism of action at estrogen receptor α of a new clinically relevant antiestrogen (GW7604) related to tamoxifen
43. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor α complex
44. The molecular pharmacology of SERMs
45. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites
46. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily
47. Steroid receptor coactivator-1 is a histone acetyltransferase
48. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor
49. A transcriptional co-repressor that interacts with nuclear hormone receptors
50. Epidermal growth factor-induced nuclear factor KB activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells
51. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBP β
52. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer
53. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium
54. Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats
55. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-α or estrogen receptor-β
56. Selective estrogen receptor modulation: A personal perspective
57. Prospects for prevention and treatment of cancer with selective PPARγ modulators (SPARMs)